Abstract
Shedding of neuroblastoma gangliosides is positively correlated with tumour progression in patients with neuroblastoma. In assessing the biological activity of these ganglioside molecules, we recently found that total human neuroblastoma gangliosides inhibit cellular immune responses. Here, we have studied the major neuroblastoma ganglioside, GD2. GD2 was purified by high performance liquid chromatography and structurally characterized by mass spectrometry. Immunoregulatory effects of GD2 in vivo were then determined in an established murine model. GD2 significantly downregulated the local cellular immune response to an allogeneic cell challenge; the usual increase in mass of the lymph node draining the injection site was reduced by 88%, from 1.52 to 0.19 mg (control versus GD2-treated mice;p<0.01). In parallel, lymphocyte recovery from each node was also reduced from 2.4 to 1.2×106 cells, and lymphocyte DNA synthesis was reduced to half of the control level. These results show that certain shed tumour gangliosides, such as GD2, function as intercellular signalling molecules, downregulate the cellular immune response, and may thereby enhance tumour formation and progression.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Travis J (1992)Science 258: 1732–33.
Ladisch S, Gillard B, Wong C, Ulsh L (1983)Cancer Res 43: 3808–13.
Ladisch S, Kitada S, Hays E (1987)J Clin Invest 79: 1879–82.
Valentino L, Moss T, Olson E, Wang H-j, Elashoff R, Ladisch S (1990)Blood 75: 1564–67.
Floutsis G, Ulsh L, Ladisch S (1988)Int J Cancer 43: 6–9.
Ladisch S, Li R, Olson E (1994)Proc Natl Acad Sci USA 91: 1974–78.
Gonwa TA, Westrick MA, Macher BA (1984)Cancer Res 44: 3467–70.
Hoon D, Irie R, Irie AC (1988)Cellular Immunol III: 410–19.
Lengle EE, Krishnaraj R, Kemp RG (1979)Cancer Res 39: 817–22.
Ryan J, Shinitzky M (1979)Eur J Immunol 9: 171–75.
Whisler R, Yates A (1980)J Immunol 125: 2106–11.
Ladisch S, Becker H, Ulsh L (1992)Biochim Biophys Acta 1125: 180–88.
Grayson G, Ladisch S (1992)Cellular Immunol 139: 18–29.
Massa PT (1993)J Exp Med 178: 1357–63.
Repke H, Barber E, Ulbricht S, Buchner K, Hucho F, Kopp R, Scholz H (1992)J Immunol 149: 2585–91.
Li R, Ladisch S (1991)Biochim Biophys Acta 1083: 57–64.
Li R, Ladisch S (1992)J Neurochem 59: 2297–303.
Ladisch R, Gillard BA (1985)Anal Biochem 146: 220–31.
Ledeen R, Yu R (1982)Methods Enzymol 83: 139–91.
Gazzotti G, Sonnino S, Ghidoni R (1985)J Chromatogr 348: 371–78.
Ladisch S, Sweeley C, Becker H, Gage D (1989)J Biol Chem 264: 12097–105.
Kroczek RA, Black CDV, Barbet J, Edison LJ, Shevach EM (1987)Transplantation 44: 547–53.
Li R, Villacreses N, Ladisch S (1995)Cancer Res 55: 211–14.
Morris RE, Wu J, Shorthouse R (1990)Transplant Proc 22: 1638–41.
Hachida M, Uwabe K, Nonoyama M, Imamaki M, Nemoto S, Hoshi H, Katsumata T, Endo M, Koyanagi H (1993)Transplantation 56: 479–82.
Ladisch S, Wu Z-L (1985)Prog Clin Biol Res 175: 277–84.
Schulz G, Cheresh D, Varki N, Yu A, Staffileno L, Reisfeld R (1984)Cancer Res 44: 5914–20.
Saito M, Yu RK, Cheung NK (1985)Biochem Biophys Res Commun 127: 1–7.
Gross N, Beck D, Portoukalian J, Favre S, Carrel S (1989)Int J Cancer 43: 665–71.
Wu Z-L, Schwartz E, Seeger R, Ladisch S (1986)Cancer Res 46: 440–43.
Ladisch S, Wu Z-L, Feig S, Ulsh L, Schwartz E, Floutsis G, Wiley F, Lenarsky C, Seeger R (1987)Int J Cancer 39: 73–76.
Ladisch S, Wu Z-L (1985)Lancet i: 136–38.
Valentino L, Ladisch S (1992)Cancer Res 52: 810–14.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Li, R., Gage, D., Mckallip, R. et al. Structural characterization andin vivo immunosuppressive activity of neuroblastoma GD2 . Glycoconjugate J 13, 385–389 (1996). https://doi.org/10.1007/BF00731471
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00731471